Table 1.
Baseline characteristics of all patients with low and intermediate–high risk of PH
| All patients with sarcoidosis (n=55) | Low risk of PH on echo (n=47) | Intermediate–high risk of PH on echo (n=8) | P-value* | |
|---|---|---|---|---|
| Age (years) | 52.7±10.1 | 51.4±10.7 | 59.9±8.3 | 0.026 |
| Female sex | 45 (81.8%) | 37 (78.7%) | 8 (100%) | 0.315 |
| BMI (kg/m2) | 30.2±5.2 | 29.5±5.0 | 33.8±5.4 | 0.043 |
| Hypertension | 11 (20%) | 9 (19.1%) | 2 (25%) | 0.651 |
| Diabetes mellitus | 11 (20%) | 8 (17.1%) | 3 (37.5%) | 0.332 |
| Smoking | 6 (10.1%) | 6 (12.8%) | - | 0.572 |
| Duration of sarcoidosis | 4.7±4.5 | 4.6±4.6 | 5.6±3.7 | 0.384 |
| Baseline NYHA ≥2 | 17 (30.1%) | 11 (20%) | 6 (75%) | 0.008 |
| Hemoglobin (gr/dL) | 13.2±1.7 | 13.3±1.5 | 12.6±2.6 | 0.442 |
| Creatinine (mg/dL) | 0.7±0.3 | 0.7±0.2 | 0.7±0.3 | 0.502 |
| Uric acid (mg/dL) | 5.3±1.6 | 5.2±1.6 | 5.6±1.9 | 0.833 |
| NT-proBNP (pg/mL) | 74.7 (207) | 63.1 (140) | 450 (1662) | 0.003 |
| Radiologic stage ≥3 | 10 (18.2%) | 7 (14.9%) | 3 (37.5%) | 0.152 |
| FEV1 (%) | 91.8±19.7 | 92.8±17.7 | 86.1±30.1 | 0.441 |
| FVC (%) | 94.2±21.3 | 94.9±18.6 | 89.9±34.4 | 0.402 |
| FEV1/FVC ratio | 1.0±0.1 | 0.98±0.1 | 0.96±0.1 | 0.984 |
| DLCO (%) | 77.2±14.6 | 78.4±14.6 | 70.0±12.5 | 0.172 |
| FVC/DLCO ratio | 1.2±0.3 | 1.23±0.3 | 1.3±0.3 | 0.930 |
| 6 MWD (m) | 426.6±89.1 | 440.9±81.7 | 342.5±89.1 | 0.007 |
| Before test O2 (%) | 96.9±3.3 | 97.8±1.2 | 91.5±6.1 | 0.001 |
| After test O2 (%) | 96.7±4.5 | 97.8±1.7 | 90.1±8.8 | <0.001 |
*
Comparison of low and intermediate–high risk of PH
6 MWD - six-minute walk distance; BMI - body mass index; DLCO - diffusing lung capacity for carbon monoxide; FEV 1 - forced expiratory volume in 1 s; FVC: forced vital capacity; LV GLS - left ventricular global longitudinal strain; NT-proBNP - N-terminal probrain natriuretic peptide; NYHA - New York Heart Association class; O2 - pulse oxygen saturation before and after the six-minute walk test; PH - pulmonary hypertension